Sulfur Nonionically Bonded Patents (Class 514/562)
  • Patent number: 11235020
    Abstract: Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anxiety disorder, substance abuse, substance dependence or substance such as an alcohol withdrawal syndrome.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: February 1, 2022
    Inventors: Abraham Palmer, Margaret Distler, Katherine M. J. McMurray
  • Patent number: 11220429
    Abstract: Systems and methods are provided for improving thermal management and/or efficiency of reaction systems including a reverse flow reactor for performance of at least one endothermic reaction and at least one supplemental exothermic reaction. The supplemental exothermic reaction can be performed in the recuperation zone of the reverse flow reactor system. By integrating the supplemental exothermic reaction into the recuperation zone, the heat generated from the supplemental exothermic reaction can be absorbed by heat transfer surfaces in the recuperation zone. The adsorbed heat can then be used to heat at least one of the fuel and the oxidant for the combustion reaction performed during regeneration, thus reducing the amount of combustion that is needed to achieve a desired temperature profile at the end of the regeneration step.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: January 11, 2022
    Assignee: ExxonMobil Research and Engineering Company
    Inventors: Anastasios I. Skoulidas, Everett J. O'Neal, Joseph E. Gatt, Anjaneya S. Kovvali
  • Patent number: 11207287
    Abstract: A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: December 28, 2021
    Assignee: IASOMAI AB
    Inventors: Tiziana Parasassi, Graziella Costa, Ewa Krasnowska, Eugenia Pittaluga
  • Patent number: 11207365
    Abstract: The present invention is related to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallization inhibitor for urine acidification, and thus preventing the pH at which supersaturation of calcium phosphate is produced and consequently, renal lithiasis.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: December 28, 2021
    Assignee: UNIVERSITAT DE LES ILLES BALEARS
    Inventors: Félix Grases Freixedas, Antonia Costa Bauzá, Rafael María Prieto Almirall, Adrián Rodríguez Rodríguez
  • Patent number: 11124490
    Abstract: The present disclosure provides novel ATX inhibitors, and pharmaceutical compositions comprising said inhibitors, as well as methods of treatment comprising administration of said inhibitors.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: September 21, 2021
    Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, UNIVERSITY OF MEMPHIS
    Inventors: Duane D. Miller, Gabor G. Tigyi, Souvik Banerjee, Abby L. Parrill-Baker
  • Patent number: 11033516
    Abstract: Disclosed herein are compositions and methods for increasing lifespan, for preventing or treating a disease including an aging-related disorder, for reducing a symptom of aging, and/or boosting an immune system in a mammal. Also disclosed herein are compositions and methods for improving effectiveness of a vaccine in a mammal. The compositions comprise, at least, a therapeutically effective amount of disulfiram and one or more additional ingredients.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: June 15, 2021
    Assignee: Spring Discovery, Inc.
    Inventors: Rachel Jacobson, Wendy Cousin, An Nguyen, Tempest Plott, William Van Trump, Dat Nguyen, Daniel Chen, Jarred Heinrich, Ben Komalo, Lauren Nicolaisen, Christian Elabd
  • Patent number: 11028138
    Abstract: Compositions and methods for using actin-based peptides to modulate cellular bioactivity, including modulation of cellular susceptibility to intracellular pathogens, such as bacteria and viruses.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: June 8, 2021
    Inventor: Yuntao Wu
  • Patent number: 10959998
    Abstract: The present invention relates to the use of pyrroloquinoline quinine (PQQ), its derivatives and/or salts for the preparation of drugs for the treatment and/or prevention of endometriosis including adenomyosis, chocolate cyst of ovary, deeply infiltrating endometriosis and other type of endometriosis. In addition, the present invention relates to the use of PQQ in combination with one or more the following antioxidants: N-Acetyl-L-cysteine (NAC), resveratrol, epigallocatechin gallate, vitamin E or vitamin C for the preparation of drugs for inhibiting the proliferation, oxidative stress status, invasion and migration of endometrial stromal cell.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: March 30, 2021
    Assignee: NANJING SHUPENG LIFESCIENCE CO., LTD.
    Inventors: Chuanjun Wen, Fenyong Sun
  • Patent number: 10874630
    Abstract: A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: December 29, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10869846
    Abstract: Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: December 22, 2020
    Assignee: SENTIENT LIFESCIENCES, INC.
    Inventor: Glenn A. Goldstein
  • Patent number: 10869855
    Abstract: A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: December 22, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10864187
    Abstract: A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: December 15, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10786542
    Abstract: Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein comprising a compound of Formula (V): wherein R1 and R2 are small peptides or modified peptides, are provided. The methods and compositions are useful in enhancing efficacy of drugs such as anti-inflammatory agents, neurological agents, thyroid agents, ocular agents, cancer chemotherapeutics, antibiotics, antimicrobials, antivirals and protease inhibitors to treat human immunodeficiency virus.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: September 29, 2020
    Inventors: Jeffrey D. Laskin, Ron Udasin, Lauren Aleksunes
  • Patent number: 10722468
    Abstract: Compositions for stabilizing and delivering proteins and/or other bioactive agents are disclosed. The bioactive agents are embedded or encapsulated in a crystalline matrix. Typically the bioactive agents are in the form of micro- or nanoparticles. The crystalline matrix confers enhanced stability to the agents embedded therein relative to other microparticulate or nanoparticulate bioactive agents. The carriers are especially useful for stabilizing bioactive macromolecules, such as proteins.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: July 28, 2020
    Assignees: BROWN UNIVERSITY, THERAPYX, INC.
    Inventors: Edith Mathiowitz, Stacia Furtado, Nejat Egilmez, Thomas Conway
  • Patent number: 10646477
    Abstract: The present invention concerns the synthesis and use of formulations of 5-substituted 2, 4-thiazolidinediones, pseudothiohydantoins, and propseudothiohydantoins and 2, 4-thiazolidinediones metforminate salts for topical and systemic treatments of infections caused by herpes simplex viruses and varicella zoster viruses.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: May 12, 2020
    Assignee: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Patent number: 10640481
    Abstract: The present invention is directed to methods for preparing Beraprost and novel synthetic intermediates for Beraprost.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: May 5, 2020
    Assignee: Lung Biotechnology PBC
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Sri Harsha Tummala, Raju Penmasta, David A. Walsh
  • Patent number: 10561673
    Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: February 18, 2020
    Assignees: Wayne State University, The United States of America as Represented by the Secretary, Department of Health and Human Service
    Inventors: Kannan Rangaramanujam, Sujatha Kannan, Roberto Romero, Raghavendra S Navath, Hui Dai, Anupa R. Menjoge
  • Patent number: 10561676
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of a dual CXCR1/2 antagonist by administering a therapeutically effective amount of a dual CXCR1/2 antagonist, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: February 18, 2020
    Assignee: Syntrix Biosystems Inc.
    Inventor: John A. Zebala
  • Patent number: 10441561
    Abstract: A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: October 15, 2019
    Assignee: The William M. Yanbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10434081
    Abstract: A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: October 8, 2019
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10420739
    Abstract: The present disclosure provides compositions and methods useful for the treatment of a body weight condition or a thyroid disorder. The compositions induces increased T3 levels while preventing thyroidal atrophy. Also provided are compositions and methods for the treatment of a disease or condition that is estrogen sensitive, estrogen receptor dependent or estrogen receptor mediated such as breast cancer.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: September 24, 2019
    Assignee: ThermoLife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 10376554
    Abstract: A powdered or liquid juice product for hangover treatment containing juiced ingredients of red onion, cucumber, and romaine lettuce. Other embodiments contain onion, cucumber, and one or more of any other leafy green vegetable. The components of the applicant's invention create a novel synergistic effect because the combination creates a greater effect than the sum of the effects of the components separately.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: August 13, 2019
    Inventor: George Jordan Laning
  • Patent number: 10376556
    Abstract: Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein comprising a compound of Formula (IV) wherein R1 and R2 are small peptides or modified peptides, are provided. The methods and compositions are useful in enhancing efficacy of drugs such as anti-inflammatory agents, neurological agents, thyroid agents, ocular agents, cancer chemotherapeutics, antibiotics, antimicrobials, antivirals and protease inhibitors to treat human immunodeficiency virus.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 13, 2019
    Inventors: Jeffrey D. Laskin, Ron Udasin, Lauren Aleksunes
  • Patent number: 10335387
    Abstract: A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: July 2, 2019
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10111852
    Abstract: A method for treating bladder cancer including the steps of administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: October 30, 2018
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10111843
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 30, 2018
    Assignees: Hough Ear Institute, Oklahoma Medical Research Foundation
    Inventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
  • Patent number: 10104882
    Abstract: Methods and compositions using 1,3-dicarbonyl compounds are disclosed for treating toxicity due to therapeutic agents and agents that causes oxidative cellular damage and for treating liver ischemia-reperfusion injury, as well as diseases and disorders that are improved through administration of N-acetylcysteine.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: October 23, 2018
    Assignee: Montefiore Medical Center
    Inventors: Richard M. LoPachin, Terrence Gavin
  • Patent number: 10092534
    Abstract: The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: October 9, 2018
    Assignee: BIOHIT OYJ
    Inventor: Osmo Suovaniemi
  • Patent number: 10080734
    Abstract: A method for treating autism and other neurodevelopmental disorders including the step of administering an effective amount of an isothiocyanate functional surfactant to a human, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. The administration of the isothiocyanate functional surfactant may be augmented with a NMDA-receptor antagonist and/or a TNF-? inhibiting agent.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: September 25, 2018
    Assignee: The William M. Yarbrough foundation
    Inventor: Michael E. Silver
  • Patent number: 9988600
    Abstract: The present invention relates to cell culture media comprising polymer embedded components. Some components show poor stability in dry powder cell culture media. Others are hygroscopic. Such components can be embedded into polymers to increase stability and reduce clumping.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: June 5, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Michael Howard Rayner-Brandes, Joerg Von Hagen
  • Patent number: 9889103
    Abstract: The present application discloses an efficient process for the preparation of N-acetyl-L-cysteine amide (NACA) starting with N-acetyl-L-cysteine.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: February 13, 2018
    Assignee: NACUITY PHARMACEUTICALS, INC.
    Inventors: John C. Warner, Srinavasa Cheruku, Sambaiah Thota, John W. Lee
  • Patent number: 9849155
    Abstract: Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein comprising a compound of Formula (VI) wherein R1 and R2 are small peptides or modified peptides, are provided. The methods and compositions are useful in enhancing efficacy of drugs such as anti-inflammatory agents, neurological agents, thyroid agents, ocular agents, cancer chemotherapeutics, antibiotics, antimicrobials, antivirals and protease inhibitors to treat human immunodeficiency virus.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: December 26, 2017
    Inventors: Jeffrey D. Laskin, Ron Udasin, Lauren Aleksunes
  • Patent number: 9840482
    Abstract: Provided herein are sulfonamide derivatives or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: December 12, 2017
    Assignee: Sunshine Lake Pharma Co., Ltd.
    Inventors: Yingjun Zhang, Chuanfei Jin, Wenhe Zhong, Hongpeng Xie, Ji Zhang
  • Patent number: 9839621
    Abstract: A method for treating bladder cancer including the steps of administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: December 12, 2017
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 9795582
    Abstract: A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: October 24, 2017
    Assignee: IASOMAI AB
    Inventors: Tiziana Parasassi, Graziella Costa, Ewa Krasnowska, Eugenia Pittaluga
  • Patent number: 9694030
    Abstract: The embodiments herein relate to a therapeutically active composition for the treatment, inhibition or attenuation of a virus. The composition comprises an effective amount of a sulfur containing compound along with one or more pharmaceutically acceptable carriers or excipients. The sulfur containing compound impairs a disulfide bond of a plurality of virus. The plurality of virus includes Ebola virus, herpes virus, dengue virus, smallpox virus, measles virus, mumps rubella virus, HIV (human immunodeficiency virus), Lassa fever virus and yellow fever virus, and even cancer, solid tumors, especially the fibrosarcoma tumor. The sulfur containing compound is sodium thiosulfate (Na2S2O3) (“STS”). The composition is given orally, intravenously, inhalation, intravesical, vaginal, rectal, sublingual, ophthalmic, or topical.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: July 4, 2017
    Inventor: Frederick J. Sawaya
  • Patent number: 9689841
    Abstract: UV-Absorbing and fluorescent pl markers for isoelectric focusing separations and fluorescent labeling, and methods for making and using the markers.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: June 27, 2017
    Assignee: The Texas A&M University System
    Inventors: Gyula Vigh, Ming-Chien Li
  • Patent number: 9650399
    Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: May 16, 2017
    Assignees: The Governing Council of the University of Toronto, UTI Limited Partnership, Indiana University Research and Technology Corporation
    Inventors: Patrick Thomas Gunning, Sina Haftchenary, Brent David George Page, Samuel Weiss, Hema Artee Luchman, Melissa L. Fishel
  • Patent number: 9585854
    Abstract: The invention relates to a new use of NAC in IVF, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in IVF is proposed.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: March 7, 2017
    Assignee: IASOMAI AB
    Inventors: Thomas Lundeberg, Tiziana Parasassi, Eugenia Pittaluga, Roberto Brunelli
  • Patent number: 9561203
    Abstract: Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: February 7, 2017
    Inventors: William Brusilow, Paolo Bernardi
  • Patent number: 9546951
    Abstract: A reducing power analysis method for minimizing peak wavelength shift in a sample, comprising a reduction step of reducing a dye reagent containing a ferric compound and a cyanide at pH conditions of 2.4 or lower in the presence of a sample; and an optical measurement step of optically measuring a peak wavelength of a reduced form of the dye reagent obtained in the reduction step.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: January 17, 2017
    Assignee: ARKRAY, Inc.
    Inventor: Kazuhiro Ohmiya
  • Patent number: 9523671
    Abstract: The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to indoxyl sulfate as a biomarker in urine of the efficacy of prebiotics for the prevention of diet induced weight gain.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 20, 2016
    Assignee: NESTEC S.A.
    Inventors: Francois-Pierre Martin, Sebastiano Collino, Ivan Montoliu Roura
  • Patent number: 9456999
    Abstract: S-allylmercapto-N-acetylcysteine and related compounds are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compounds include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: October 4, 2016
    Assignee: Allium Vitalis, Inc.
    Inventor: David Michael Ott
  • Patent number: 9326960
    Abstract: Disclosed is a composition for preventing or treating eye diseases. The composition for preventing or treating eye diseases contains S-allyl-L-cysteine, a pharmaceutically acceptable salt thereof, or a solvate or a hydrate thereof as an active ingredient, and may inhibit photo-oxidation. The composition for preventing or treating eye diseases inhibits the accumulation of A2E in retinal pigment epithelial cells and the oxidation of A2E, thereby remarkably preventing or treating eye diseases including age-related macular degeneration or degenerative retinal disorder.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: May 3, 2016
    Assignee: PHARMAKING CO., LTD.
    Inventors: Soon Bae Kim, Gwang Soon Kim, Wan Bae Kim, Wie Jong Kwak, Sun Duck Jeon, Hyung Young Yoon, Young Pyo Jang
  • Patent number: 9249448
    Abstract: The invention pertains to the field of reaction systems generating malodor, particularly from constituents of human sweat. Specifically, the invention pertains to proteins for generating malodors, substrates for generating such malodor, inhibitors of such malodor generation and test and screening systems for measuring their malodor inhibition efficacy and finding substances previously not known to inhibit malodor generation. Thus, the invention also pertains to the field of deodorants.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: February 2, 2016
    Assignee: BASF SE
    Inventor: Markus Pompejus
  • Patent number: 9216163
    Abstract: A novel angiogenesis inhibitor, and a method for inhibiting angiogenesis are provided. Also provided are a prophylactic or therapeutic agent for a disease accompanied by angiogenesis, and a method for preventing or treating a disease accompanied by angiogenesis. The angiogenesis inhibitor contains L-carbocisteine or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: December 22, 2015
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Keizo Sato, Tomohiro Shinya, Shiori Nakayama
  • Patent number: 9155301
    Abstract: The invention relates to an antimicrobial agent where a cysteine compound is covalently bound to a substrate, in particular by binding through an S—S bridge via a spacer molecule to the substrate. The spacer comprises a carbon chain, optionally interrupted by one or more heteroatoms, e.g. O, S, N, P and Si; the chain is optionally substituted with one or more alkyl groups, preferably lower alkyl groups with 1-5 carbon atoms, hydroxyl groups or alkoxy groups. Also, the invention refers to a substrate that is coated with the antimicrobial agent of the invention. The agent has excellent antimicrobial properties and can be used to coat surfaces and substrates of various devices, such as medical devices or devices used in food handling, in order to prevent or inhibit accumulation and/or growth and/or proliferation and/or the viability of microorganisms and/or formation of biofilm.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: October 13, 2015
    Assignee: CYTACOAT AB
    Inventors: Anders Wirsen, Birgitta Agerberth, Gudmundur Gudmundsson, Jacob Odeberg, Torbjorn Lindberg
  • Patent number: 9139512
    Abstract: The degradation of an absorbent solution comprising organic compounds with an amine functional group in aqueous solution is substantially reduced in the presence of a small amount of degradation inhibiting agents belonging to the family of derivatives of triazoles or of a tetrazole at least one substituent of which contains a sulfur atom. The absorbent solution is used to deacidize a gaseous effluent.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: September 22, 2015
    Assignee: IFP ENERGIES NOUVELLES
    Inventors: P.-Louis Carrette, Bruno Delfort
  • Patent number: 9119821
    Abstract: Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: September 1, 2015
    Inventors: William Brusilow, Paolo Bernardi
  • Patent number: 9066914
    Abstract: An object of the present invention is to provide a prophylactic or ameliorating agent for pigmentation having a novel scaffold and an external preparation for skin containing the same as a component.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: June 30, 2015
    Assignee: POLA CHEMICAL INDUSTRIES INC.
    Inventors: Takashi Yamasaki, Yuko Saitoh, Chihiro Kondo